MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

Search

Adaptive Biotechnologies Corp

Затворен

15.55

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

15.16

Максимум

15.75

Ключови измерители

By Trading Economics

Приходи

4.2M

-26M

Продажби

6.4M

59M

Марж на печалбата

-43.467

Служители

619

EBITDA

11M

-18M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

-3.23% downside

Дивиденти

By Dow Jones

Следващи печалби

6.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

703M

2.4B

Предишно отваряне

15.55

Предишно затваряне

15.55

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.10.2025 г., 22:33 ч. UTC

Печалби

America Movil 3Q Profit Jumps on Higher Revenue, Lower Financial Costs

14.10.2025 г., 22:21 ч. UTC

Значими двигатели на пазара

Dentsply Sirona Shares Rise After SEC Probe Ends

14.10.2025 г., 19:27 ч. UTC

Придобивния, сливания и поглъщания

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20 Billion

14.10.2025 г., 17:56 ч. UTC

Значими двигатели на пазара

Nova Minerals Surges; Will Provide Minerals Briefing to Australian Government Ahead of Trump Meeting

14.10.2025 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Rise Amid Possible Bargain-Hunting -- Market Talk

14.10.2025 г., 22:12 ч. UTC

Пазарно говорене
Печалби

Fletcher Building's 1H Earnings Likely Down 16% -- Market Talk

14.10.2025 г., 21:40 ч. UTC

Печалби

America Movil 3Q EBITDA MXN93.82B, Up 4.9% on Year >AMX.MX

14.10.2025 г., 21:39 ч. UTC

Печалби

America Movil 3Q Rev MXN232.92B, Up 4.2% on Year >AMX.MX

14.10.2025 г., 21:38 ч. UTC

Печалби

America Movil 3Q Net MXN22.7B Vs. Net MXN6.43B Year Ago >AMX.MX

14.10.2025 г., 21:06 ч. UTC

Печалби

These Stocks Moved the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14.10.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Financial Services Roundup: Market Talk

14.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

14.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

14.10.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Health Care Roundup: Market Talk

14.10.2025 г., 20:13 ч. UTC

Печалби

BlackRock's Assets Hit Record $13.5 Trillion After Market Rally, Dealmaking Spree -- 2nd Update

14.10.2025 г., 20:01 ч. UTC

Печалби

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 5th Update

14.10.2025 г., 19:21 ч. UTC

Пазарно говорене
Печалби

Citigroup's Higher Outlook Leaves Questions -- Market Talk

14.10.2025 г., 19:12 ч. UTC

Придобивния, сливания и поглъщания

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20B

14.10.2025 г., 19:08 ч. UTC

Пазарно говорене

Oil Futures Settle Lower on Trade, Oversupply Concerns -- Market Talk

14.10.2025 г., 19:02 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls as Weather Outlook Stays Mild -- Market Talk

14.10.2025 г., 18:59 ч. UTC

Придобивния, сливания и поглъщания

Bouygues Telecom, Free-iliad Group, Orange Bid for Corresponds to Total Enterprise Value of EUR17B for Altice France Assets

14.10.2025 г., 18:58 ч. UTC

Придобивния, сливания и поглъщания

Bouygues Telecom, Free-iliad Group, Orange Bid Excludes Stakes in Intelcia, UltraEdge, XP Fibre, Altice Technical Services

14.10.2025 г., 18:58 ч. UTC

Придобивния, сливания и поглъщания

Bouygues Telecom, Free-iliad Group, Orange Bid Covers Most SFR Assets

14.10.2025 г., 18:56 ч. UTC

Придобивния, сливания и поглъщания

Bouygues Telecom, Free-iliad Group, Orange Submit Joint Non-Binding Offer to Buy Large Part of Altice's Activities in France

14.10.2025 г., 18:46 ч. UTC

Печалби

These Stocks Are Moving the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14.10.2025 г., 18:04 ч. UTC

Печалби

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 4th Update

14.10.2025 г., 18:01 ч. UTC

Пазарно говорене

Gold Finds Another Record as Traders Eye Further Upside -- Market Talk

14.10.2025 г., 17:54 ч. UTC

Печалби

Salesforce's Dreamforce Conference Kicks Off. CEO Benioff Touts AI Tool Agentforce. -- Barrons.com

14.10.2025 г., 17:50 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

14.10.2025 г., 17:50 ч. UTC

Пазарно говорене

Lower Dollar Provides Some Strength in Grains -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

-3.23% надолу

12-месечна прогноза

Среден 15 USD  -3.23%

Висок 20 USD

Нисък 11 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

7

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

8.81 / 10.18Подкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Weak Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
help-icon Live chat